Skip to main content

Sprint and T-Mobile Getting Scrod?

Old joke.

A traveller who is a huge fan of seafood arrives in Boston for the first time.  He leaves the airport and hails a cab.  After he gets in, he excitedly says to the cabbie, "Hey, I'm new in town.  Can you tell me a good place to go to get scrod?"  The cabbie replies [in a thick Boston accent], "Pal, I've got to congratulate you.  I've heard that question a lot over the years, but that's the first time I've ever heard it in the pluperfect subjunctive."

That joke is so old that it was first told in an era when large numbers of people could explain what the pluperfect subjunctive is. [You can google it if you like, but of course it won't help. You either find the joke funny or not regardless.]

Anyway, I can't help but wonder how badly T-Mobile and Sprint are finding themselves scrod by the recent FCC ruling on an airwaves auction.

So far as I understand it -- The FCC has set the rules so that most of the available bits of wirelessness will end up sold either to Verizon or AT&T. The two second-tier companies, T-Mobile and Sprint, will get something, but they will remain clearly second tier firms when its over. Indeed, the rules seem to lock the tiers into place.

Also, the rules came along with a stern admonition against merging. Presumably if Sprint and T-Mobile did merge then the combined firm could be in some sense first tier, entitled to a seat at the grown-up table at this auction. But no ... that's not allowed. The rules are designed so that the FCC can re-write them to the disadvantage of any parties that seek to merge with each other while the auction is pending. According to the news account to which I've just linked you, one FTC commissioner, Ajit Pai, said: "We all know what the item has in mind here."

What the item has in mind. A strange expression: does the agenda item itself have intentions? Does it have a mind?

Anyway, it seems that the FCC is telling those two firms that not only have they been consigned to the kiddy table, but that any effort to move to the adult table will get them exiled from the feast altogether.

Somebody tell me if I misunderstand.


Popular posts from this blog

A Story About Coleridge

This is a quote from a memoir by Dorothy Wordsworth, reflecting on a trip she took with two famous poets, her brother, William Wordsworth, and their similarly gifted companion, Samuel Taylor Coleridge.

We sat upon a bench, placed for the sake of one of these views, whence we looked down upon the waterfall, and over the open country ... A lady and gentleman, more expeditious tourists than ourselves, came to the spot; they left us at the seat, and we found them again at another station above the Falls. Coleridge, who is always good-natured enough to enter into conversation with anybody whom he meets in his way, began to talk with the gentleman, who observed that it was a majestic waterfall. Coleridge was delighted with the accuracy of the epithet, particularly as he had been settling in his own mind the precise meaning of the words grand, majestic, sublime, etc., and had discussed the subject with William at some length the day before. “Yes, sir,” says Coleridge, “it is a majestic wate…

Cancer Breakthrough

Hopeful news in recent days about an old and dear desideratum: a cure for cancer. Or at least for a cancer, and a nasty one at that.

The news comes about because investors in GlaxoSmithKline are greedy for profits, and has already inspired a bit of deregulation to boot. 

The FDA has paved the road for a speedy review of a new BCMA drug for multiple myeloma, essentially cancer of the bone marrow. This means that the US govt has removed some of the hurdles that would otherwise (by decision of the same govt) face a company trying to proceed with these trials expeditiously. 

This has been done because the Phase I clinical trial results have been very promising. The report I've seen indicates that details of these results will be shared with the world on Dec. 11 at the annual meeting of the American Society of Hematology. 

The European Medicines Agency has also given priority treatment to the drug in question. 

GSK's website identifies the drug at issue as "GSK2857916," althou…

Hume's Cutlery

David Hume is renowned for two pieces of cutlery, the guillotine and the fork.

Hume's guillotine is the sharp cut he makes between "is" statements and "ought" statements, to make the point that the former never ground the latter.

His "fork" is the division between what later came to be called "analytic" and "synthetic" statements, with the ominous observation that any books containing statements that cannot be assigned to one or the other prong should be burnt.

Actually, I should acknowledge that there is some dispute as to how well or poorly the dichotomy Hume outlines really maps onto the analytic/synthetic dichotomy. Some writers maintain that Hume meant something quite different and has been hijacked. Personally, I've never seen the alleged difference however hard they've worked to point it out to me.

The guillotine makes for a more dramatic graphic than a mere fork, hence the bit of clip art above.

I'm curious whe…